Skip to main content

The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).

 

THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.

 

To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.

 

By clicking on the "Accept" button below, you will be deemed to have made this confirmation

 

Bonds

Issuer Volume in millionCouponMaturity

Fresenius SE & Co. KGaA

 €450 4.00% 2024

Fresenius SE & Co. KGaA

 €500 1.875% 2025

Fresenius SE & Co. KGaA

 €750 1.875% 2025

Fresenius SE & Co. KGaA

 €500 0.375% 2026

Fresenius SE & Co. KGaA

 €750 1.625% 2027

Fresenius SE & Co. KGaA

 €750 0.75% 2028

Fresenius SE & Co. KGaA

 €500 2.875% 2029

Fresenius SE & Co. KGaA

 €550 2.875% 2030

Fresenius SE & Co. KGaA

 €500 1.125% 2033

Fresenius Finance Ireland plc.

 €700 1.50% 2024

Fresenius Finance Ireland plc.

 €500 0.00% 2025

Fresenius Finance Ireland plc.

 €700 2.125% 2027

Fresenius Finance Ireland plc.

 €500 0.50% 2028

Fresenius Finance Ireland plc.

 €500 0.875% 2031

Fresenius Finance Ireland plc.

 €500 3.00% 2032

Fresenius US Finance II, Inc.

 $300 4.50% 2023

Fresenius Medical Care US Finance II, Inc.

 $400 4.75% 2024

Fresenius Medical Care US Finance III, Inc.

 $850 1,875% 2026

Fresenius Medical Care US Finance III, Inc

 $500 3.75% 2029

Fresenius Medical Care US Finance III, Inc.

 $650 3.000% 2031

Fresenius Medical Care US Finance III, Inc

 $1,000 2.375% 2031

Fresenius Medical Care AG & Co. KGaA

 €6500.250% 2023

Fresenius Medical Care AG & Co. KGaA

 €500 1.50% 2025

Fresenius Medical Care AG & Co. KGaA

 €500 1.000% 2026

Fresenius Medical Care AG & Co. KGaA

 €600 0.625% 2026

Fresenius Medical Care AG & Co. KGaA

 €500 1.250% 2029

Fresenius Medical Care AG & Co. KGaA

 €750 1.500% 2030

Issuer Fresenius SE & Co. KGaA

Currency

Issue amount

 500,000,000

Value date

 January 31, 2017

Maturity

 January 31, 2024

Coupon

 0 %

Issue price

 101.00%

Rating

 BBB / Baa3 / BBB-

Actual conversion price

 €104.2835

Actual conversion ratio

 958.92447

Conversion period

 From August 31, 2023 until November 7, 2023

Conversion

 Cash settled

Stock exchange

 Frankfurt / Open Market (Freiverkehr)

Denomination

 €100,000

Clearing agency

 Clearstream Frankfurt

ISIN

 DE000A2DAHU1

  • Any increase of Fresenius' share price above the conversion price would be offset by a corresponding value increase of the call options; dilution of Fresenius' share capital through issuance of new shares in connection with this transaction is ruled out.